Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
К вопросу о терапии пациентов с симптомами нижних мочевых путей на фоне доброкачественной гиперплазии предстательной железы с сочетанной эректильной дисфункцией
К вопросу о терапии пациентов с симптомами нижних мочевых путей на фоне доброкачественной гиперплазии предстательной железы с сочетанной эректильной дисфункцией
Цуканов А.Ю., Семикина С.П. К вопросу о терапии пациентов с симптомами нижних мочевых путей на фоне доброкачественной гиперплазии предстательной железы с сочетанной эректильной дисфункцией. Consilium Medicum. 2019; 21 (7): 81–85. DOI: 10.26442/20751753.2019.7.190560
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Представленный обзор литературы посвящен анализу данных по результатам клинического использования препарата группы ингибиторов фосфодиэстеразы 5-го типа при консервативном лечении пациентов с сочетанием доброкачественной гиперплазии предстательной железы и эрек-тильной дисфункции. Показана патофизиологическая общность механизмов, поддерживающих и обеспечивающих развитие и основные проявле-ния этих двух заболеваний и, как следствие, жалоб, предъявляемых пациентами. Приведено патофизиологическое обоснование применения представителей препаратов группы ингибиторов фосфодиэстеразы 5-го типа, среди которых явные конкурентные преимущества имеет молекула тадалафила в связи с ее фармакологическими и фармакокинетическими особенностями, в частности временем полувыведения. Приведены данные доклинических и клинических международных исследований, в которых проанализированы различные варианты применения тадалафила: как в виде монотерапии, так и в комбинации с основными используемыми препаратами при нарушенном мочеиспускании – a1-адреноблокатором и ингибитором 5a-редуктазы. В обзоре приведены данные основных работ, дизайн которых отвечает современным требованиям доказательной медицины. Все указанные варианты применения этого препарата в лечении пациентов с нарушенным мочеиспусканием на фоне аденомы проста-ты в сочетании с эректильной дисфункцией имеют достаточно высокие показатели эффективности и благоприятный профиль безопасности.
Ключевые слова: доброкачественная гиперплазия предстательной железы, эректильная дисфункция, ингибиторы фосфодиэстеразы 5-го типа, тадалафил.
Ключевые слова: доброкачественная гиперплазия предстательной железы, эректильная дисфункция, ингибиторы фосфодиэстеразы 5-го типа, тадалафил.
________________________________________________
The presented literature review deals with the analysis of data on clinical use of a drug from the group of phosphodiesterase enzyme 5 inhibitors in the conser-vative treatment of patients with a combination of benign prostatic hyperplasia and erectile dysfunction. A similarity of pathophysiological mechanisms which provide and support main manifestations of these two diseases and, as a consequence, complaints presented by patients are showed. The pathophysiological rationale for the use of drugs from the group of phosphodiesterase enzyme 5 inhibitors is given, among which the tadalafil molecule has obvious competitive ad-vantages due to its pharmacological and pharmacokinetic characteristics, in particular the half-life. The data of preclinical and clinical international studies are presented, in which various applications of tadalafil are analyzed: both in the form of monotherapy and in combination with the main drugs used for impaired uri-nation – alpha-1-blocker and 5a-reductase inhibitor. The review provides data on the main studies which design meets the modern requirements of evidence-based medicine. All of these options for the use of this drug for the treatment of patients with impaired urination against a background of prostate adenoma in combination with erectile dysfunction have fairly high efficacy criteria and a favorable safety profile.
Key words: benign prostatic hyperplasia, erectile dysfunction, phosphodiesterase enzyme 5 inhibitors, tadalafil.
Key words: benign prostatic hyperplasia, erectile dysfunction, phosphodiesterase enzyme 5 inhibitors, tadalafil.
Полный текст
Список литературы
1. Gratzke C, Bachmann A, Descazeaud A et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2015; 67: 1099–109.
2. Gacci M et al. PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH. Curr Bladder Dysfunction Rep 2013; 8: 150–9.
3. Gacci M et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011; 60: 809–25.
4. Mondul AM, Rimm EB, Giovannucci E et al. A Prospective Study of Lower Urinary Tract Symptoms and Erectile Dysfunction. J Urol 2008; 179 (6): 2321–6.
5. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281 (6): 537–44.
6. Blanker MH, Bohnen AM, Groeneveld FP et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001; 49 (4): 436–42.
7. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44 (6): 637–49.
8. Камалов А.А., Тахирзаде А.М. Современные подходы к консервативному лечению мужчин с сочетанием доброкачественной гиперплазии предстательной железы и эректильной дисфункции. Урология. 2017; 6: 160–3.
[Kamalov A.A., Takhirzade A.M. Sovremennye podkhody k konservativnomu lecheniiu muzhchin s sochetaniem dobrokachestvennoi giperplazii predstatel'noi zhelezy i erektil'noi disfunktsii. Urologiia. 2017; 6: 160–3 (in Russian).]
9. Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol 2011; 483–94.
10. Daneshgari F, Liu G, Hanna-Mitchell AT. Path of translational discovery of urological complications of obesity and diabetes. Am J Physiol – Ren Physiol 2017; 312: F887–F896.
11. Lu T, Lin W-J, Izumi K et al. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Mol Endocrinol 2012; 26: 1707–15.
12. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 2012; 367: 248–57.
13. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401–7.
14. Toque HA, Teixeira CE, Priviero FBM et al. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol 2008; 154: 787–96.
15. Toque HA, Teixeira CE, Lorenzetti R et al. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol 2008; 591: 189–95.
16. Toque HA, Priviero FBM, Teixeira CE et al. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release. Urology 2009; 74: 216–21.
17. Venneri MA, Giannetta E, Panio G et al. Chronic inhibition of PDE5 limits pro-inflammatory monocyte-macrophage polarization in streptozotocin-induced diabetic mice. PLoS One 2015; 10.
18. Mokry J, Urbanova A, Medvedova I et al. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs. J Physiol Pharmacol. 2017; 68: 721–30.
19. Islam BN, Sharman SK, Hou Y et al. Sildenafil suppresses inflammation-driven colorectal cancer in mice. Cancer Prev Res 2017; 10: 377–88.
20. El-Naa MM, Othman M, Younes S. Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis. Drug Des Devel Ther 2016; 10: 3661.
21. Dorey G. Are erectile and ejaculatory dysfunction associated with postmicturition dribble? Urol Nurs 2003; 23: 42–5, 48–52.
22. De Nunzio C, Roehrborn CG, Andersson KE, McVary KT. Erectile dysfunction and lower urinary tract symptoms. Eur Urol Focus 2017; 3: 352–63.
23. Sexton CC, Coyne KS, Kopp ZS et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009; 103 (Suppl. 3): 12–23.
24. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306–14.
25. Maserejian NN, Kupelian V, McVary KT et al. Prevalence of postmicturition symptoms in association with lower urinary tract symptoms and health-related quality of life in men and women. BJU Int 2011; 108: 1452–8.
26. Poyhonen A, Auvinen A, Koskimaki J et al. Prevalence and bother of postmicturition dribble in finnish men aged 30–80 years: tampere ageing male urologic study (TAMUS). Scand J Urol Nephrol 2012; 46: 418–23.
27. Coyne KS, Sexton CC, Thompson CL et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int 2009; 104: 352–60.
28. Agarwal A, Eryuzlu LN, Cartwright R et al. What is the most bothersome lower urinary tract symptom? Individual- and populationlevel perspectives for both men and women. Eur Urol 2014; 65: 1211–7.
29. Poyhonen A, Auvinen A, Hakkinen JT et al. Population-level and individual-level bother of lower urinary tract symptoms among 30- to 80-year-old men. Urology 2016; 95: 164–70.
30. Yang DY, Ko K, Lee SH et al. Postmicturition dribble is associated with erectile dysfunction in middle-aged and older men with lower urinary tract symptoms. World J Mens Health 2018; 36: 263–70.
31. Macfarlane GJ, Botto H, Sagnier PP et al. The relationship between sexual life and urinary condition in the French community. J Clin Epidemiol 1996; 49: 1171–6.
32. Frankel SJ, Donovan JL, Peters TI et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998; 51: 677–85.
33. Shafik A, Shafik IA, El Sibai O, Shafik AA. Study of the response of the penile corporal tissue and cavernosus muscles to micturition. BMC Urol 2008; 8: 4.
34. Ferrer JE, Velez JD, Herrera AM. Age-related morphological changes in smooth muscle and collagen content in human corpus cavernosum. J Sex Med 2010; 7: 2723–8.
35. Costa C, Vendeira P. Does erectile tissue angioarchitecture modify with aging? An immunohistological and morphometric approach. J Sex Med 2008; 5: 833–40.
36. Giuliano F, Uckert S, Maggi M et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 2013; 63: 506–16.
37. Урология. Российские клинические рекомендации. Под ред. Ю.Г.Аляева, П.В.Глыбочко, Д.Ю.Пушкаря. М., 2017.
[Urology. Russian clinical guidelines. Ed.: Yu.G.Alaev, P.V.Glybochko, D.Y.Pushkar. Moscow, 2017 (in Russian).]
38. Говоров А.В., Касян Г.Р., Васильев А.О., Пушкарь Д.Ю. Тадалафил в лечении симптомов со стороны нижних мочевых путей: обзор литературы и существующей клинической практики в России. Consilium Medicum. 2014; 16 (7): 33–41.
[Govorov A.V., Kasyan G.R., Vasil’ev A.O., Pushkar D.Yu. Adalafil in the treatment of symptoms from the lower urinary tract: a review of literature and existing clinical practice in Russia. Consilium Medicum. 2014; 16 (7): 33–41 (in Russian).]
39. Камалов А.А., Охоботов Д.А., Тахирзаде А.М. и др. Комбинированная терапия больных с симптомами нижних мочевых путей и эректильной дисфункцией. Естественные и технические науки. 2013; 1: 105–13.
[Kamalov A.A., Okhobotov D.A., Takhirzade A.M. et al. Kombinirovannaia terapiia bol'nykh s simptomami nizhnikh mochevykh putei i erektil'noi disfunktsiei. Estestvennye i tekhnicheskie nauki. 2013; 1: 105–13 (in Russian).]
40. Gacci M, Andersson KE, Chapple C et al. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol 2016; 70 (1): 124–33.
41. Brock GB, McVary KT, Roehrborn CG et al. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. J Urol 2014; 191 (2): 405–11.
42. Gacci MI, Corona G, Salvi M et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61 (5): 994–1003.
43. Giuliano FI, Oelke M, Jungwirth A et al. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study. J Sex Med 2013; 10 (3): 857–65.
44. European association of urology. Guidelines. Management of Non-neurogenic Male LUTS. S. Gravas (Chair), J.N. Cornu, M. Gacci, C. Gratzke, T.R.W. Herrmann, C. Mamoulakis, M. Rieken, M.J. Speakman, K.A.O. Tikkinen, 2019.
45. Mujoo K, Sharin VG, Martin E et al. Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation. Nitric Oxide – Biol Chem 2010; 22: 43–50.
46. Sotolongo A, Mónica FZ, Kots A et al. Epigenetic regulation of soluble guanylate cyclase (sGC) b1 in breast cancer cells. FASEB J 2016; 30: 3171–80.
47. Lin JE, Li P, Snook AE et al. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology 2010; 138: 241–54.
48. Rappaport JA, Waldman SA. The guanylate cyclase C – cGMP signaling axis opposes intestinal epithelial injury and neoplasia. Front Oncol 2018; 8: 299.
49. Liu N, Mei L, Fan X et al. Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway. Cancer Lett 2016; 378: 38–50.
50. Egerdie RB, Auerbach S, Roehrborn CG et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, doubleblind study. J Sex Med 2012; 9: 271–81.
51. Волков А.А., М.И. Петричко, Н.В. Будник. Ежедневный прием ингибиторов фосфодиэстеразы 5-го типа – коррекция эректильной дисфункции и симптомов нижних мочевых путей у больных аденомой предстательной железы. Урология. 2014; 4: 64–8.
[Volkov A.A., Petrichko M.I., Budnik N.V. Daily use of type 5 phosphodiesterase inhibitors – correction of erectile dysfunction and lower urinary tract symptoms in patients with prostate adenoma. Urologija. 2014; 4: 64–8 (In Russian).]
52. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401–7.
53. Bechara A, Romano S, Casabé A et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008; 5: 2170–8.
54. Porst H, McVary KT, Montorsi F et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56: 727–36.
55. Roehrborn CG, McVary KT, Elion-Mboussa A et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228–34.
2. Gacci M et al. PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH. Curr Bladder Dysfunction Rep 2013; 8: 150–9.
3. Gacci M et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011; 60: 809–25.
4. Mondul AM, Rimm EB, Giovannucci E et al. A Prospective Study of Lower Urinary Tract Symptoms and Erectile Dysfunction. J Urol 2008; 179 (6): 2321–6.
5. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281 (6): 537–44.
6. Blanker MH, Bohnen AM, Groeneveld FP et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001; 49 (4): 436–42.
7. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44 (6): 637–49.
8. Kamalov A.A., Takhirzade A.M. Sovremennye podkhody k konservativnomu lecheniiu muzhchin s sochetaniem dobrokachestvennoi giperplazii predstatel'noi zhelezy i erektil'noi disfunktsii. Urologiia. 2017; 6: 160–3 (in Russian).
9. Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol 2011; 483–94.
10. Daneshgari F, Liu G, Hanna-Mitchell AT. Path of translational discovery of urological complications of obesity and diabetes. Am J Physiol – Ren Physiol 2017; 312: F887–F896.
11. Lu T, Lin W-J, Izumi K et al. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Mol Endocrinol 2012; 26: 1707–15.
12. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 2012; 367: 248–57.
13. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401–7.
14. Toque HA, Teixeira CE, Priviero FBM et al. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol 2008; 154: 787–96.
15. Toque HA, Teixeira CE, Lorenzetti R et al. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol 2008; 591: 189–95.
16. Toque HA, Priviero FBM, Teixeira CE et al. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release. Urology 2009; 74: 216–21.
17. Venneri MA, Giannetta E, Panio G et al. Chronic inhibition of PDE5 limits pro-inflammatory monocyte-macrophage polarization in streptozotocin-induced diabetic mice. PLoS One 2015; 10.
18. Mokry J, Urbanova A, Medvedova I et al. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs. J Physiol Pharmacol. 2017; 68: 721–30.
19. Islam BN, Sharman SK, Hou Y et al. Sildenafil suppresses inflammation-driven colorectal cancer in mice. Cancer Prev Res 2017; 10: 377–88.
20. El-Naa MM, Othman M, Younes S. Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis. Drug Des Devel Ther 2016; 10: 3661.
21. Dorey G. Are erectile and ejaculatory dysfunction associated with postmicturition dribble? Urol Nurs 2003; 23: 42–5, 48–52.
22. De Nunzio C, Roehrborn CG, Andersson KE, McVary KT. Erectile dysfunction and lower urinary tract symptoms. Eur Urol Focus 2017; 3: 352–63.
23. Sexton CC, Coyne KS, Kopp ZS et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009; 103 (Suppl. 3): 12–23.
24. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306–14.
25. Maserejian NN, Kupelian V, McVary KT et al. Prevalence of postmicturition symptoms in association with lower urinary tract symptoms and health-related quality of life in men and women. BJU Int 2011; 108: 1452–8.
26. Poyhonen A, Auvinen A, Koskimaki J et al. Prevalence and bother of postmicturition dribble in finnish men aged 30–80 years: tampere ageing male urologic study (TAMUS). Scand J Urol Nephrol 2012; 46: 418–23.
27. Coyne KS, Sexton CC, Thompson CL et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int 2009; 104: 352–60.
28. Agarwal A, Eryuzlu LN, Cartwright R et al. What is the most bothersome lower urinary tract symptom? Individual- and populationlevel perspectives for both men and women. Eur Urol 2014; 65: 1211–7.
29. Poyhonen A, Auvinen A, Hakkinen JT et al. Population-level and individual-level bother of lower urinary tract symptoms among 30- to 80-year-old men. Urology 2016; 95: 164–70.
30. Yang DY, Ko K, Lee SH et al. Postmicturition dribble is associated with erectile dysfunction in middle-aged and older men with lower urinary tract symptoms. World J Mens Health 2018; 36: 263–70.
31. Macfarlane GJ, Botto H, Sagnier PP et al. The relationship between sexual life and urinary condition in the French community. J Clin Epidemiol 1996; 49: 1171–6.
32. Frankel SJ, Donovan JL, Peters TI et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998; 51: 677–85.
33. Shafik A, Shafik IA, El Sibai O, Shafik AA. Study of the response of the penile corporal tissue and cavernosus muscles to micturition. BMC Urol 2008; 8: 4.
34. Ferrer JE, Velez JD, Herrera AM. Age-related morphological changes in smooth muscle and collagen content in human corpus cavernosum. J Sex Med 2010; 7: 2723–8.
35. Costa C, Vendeira P. Does erectile tissue angioarchitecture modify with aging? An immunohistological and morphometric approach. J Sex Med 2008; 5: 833–40.
36. Giuliano F, Uckert S, Maggi M et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 2013; 63: 506–16.
37. Urology. Russian clinical guidelines. Ed.: Yu.G.Alaev, P.V.Glybochko, D.Y.Pushkar. Moscow, 2017 (in Russian).
38. Govorov A.V., Kasyan G.R., Vasil’ev A.O., Pushkar D.Yu. Adalafil in the treatment of symptoms from the lower urinary tract: a review of literature and existing clinical practice in Russia. Consilium Medicum. 2014; 16 (7): 33–41 (in Russian).
39. Kamalov A.A., Okhobotov D.A., Takhirzade A.M. et al. Kombinirovannaia terapiia bol'nykh s simptomami nizhnikh mochevykh putei i erektil'noi disfunktsiei. Estestvennye i tekhnicheskie nauki. 2013; 1: 105–13 (in Russian).
40. Gacci M, Andersson KE, Chapple C et al. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol 2016; 70 (1): 124–33.
41. Brock GB, McVary KT, Roehrborn CG et al. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. J Urol 2014; 191 (2): 405–11.
42. Gacci MI, Corona G, Salvi M et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61 (5): 994–1003.
43. Giuliano FI, Oelke M, Jungwirth A et al. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study. J Sex Med 2013; 10 (3): 857–65.
44. European association of urology. Guidelines. Management of Non-neurogenic Male LUTS. S. Gravas (Chair), J.N. Cornu, M. Gacci, C. Gratzke, T.R.W. Herrmann, C. Mamoulakis, M. Rieken, M.J. Speakman, K.A.O. Tikkinen, 2019.
45. Mujoo K, Sharin VG, Martin E et al. Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation. Nitric Oxide – Biol Chem 2010; 22: 43–50.
46. Sotolongo A, Mónica FZ, Kots A et al. Epigenetic regulation of soluble guanylate cyclase (sGC) b1 in breast cancer cells. FASEB J 2016; 30: 3171–80.
47. Lin JE, Li P, Snook AE et al. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology 2010; 138: 241–54.
48. Rappaport JA, Waldman SA. The guanylate cyclase C – cGMP signaling axis opposes intestinal epithelial injury and neoplasia. Front Oncol 2018; 8: 299.
49. Liu N, Mei L, Fan X et al. Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway. Cancer Lett 2016; 378: 38–50.
50. Egerdie RB, Auerbach S, Roehrborn CG et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, doubleblind study. J Sex Med 2012; 9: 271–81.
51. Volkov A.A., Petrichko M.I., Budnik N.V. Daily use of type 5 phosphodiesterase inhibitors – correction of erectile dysfunction and lower urinary tract symptoms in patients with prostate adenoma. Urologija. 2014; 4: 64–8 (In Russian).
52. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401–7.
53. Bechara A, Romano S, Casabé A et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008; 5: 2170–8.
54. Porst H, McVary KT, Montorsi F et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56: 727–36.
55. Roehrborn CG, McVary KT, Elion-Mboussa A et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228–34.
2. Gacci M et al. PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH. Curr Bladder Dysfunction Rep 2013; 8: 150–9.
3. Gacci M et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011; 60: 809–25.
4. Mondul AM, Rimm EB, Giovannucci E et al. A Prospective Study of Lower Urinary Tract Symptoms and Erectile Dysfunction. J Urol 2008; 179 (6): 2321–6.
5. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281 (6): 537–44.
6. Blanker MH, Bohnen AM, Groeneveld FP et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001; 49 (4): 436–42.
7. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44 (6): 637–49.
8. Камалов А.А., Тахирзаде А.М. Современные подходы к консервативному лечению мужчин с сочетанием доброкачественной гиперплазии предстательной железы и эректильной дисфункции. Урология. 2017; 6: 160–3.
[Kamalov A.A., Takhirzade A.M. Sovremennye podkhody k konservativnomu lecheniiu muzhchin s sochetaniem dobrokachestvennoi giperplazii predstatel'noi zhelezy i erektil'noi disfunktsii. Urologiia. 2017; 6: 160–3 (in Russian).]
9. Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol 2011; 483–94.
10. Daneshgari F, Liu G, Hanna-Mitchell AT. Path of translational discovery of urological complications of obesity and diabetes. Am J Physiol – Ren Physiol 2017; 312: F887–F896.
11. Lu T, Lin W-J, Izumi K et al. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Mol Endocrinol 2012; 26: 1707–15.
12. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 2012; 367: 248–57.
13. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401–7.
14. Toque HA, Teixeira CE, Priviero FBM et al. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol 2008; 154: 787–96.
15. Toque HA, Teixeira CE, Lorenzetti R et al. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol 2008; 591: 189–95.
16. Toque HA, Priviero FBM, Teixeira CE et al. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release. Urology 2009; 74: 216–21.
17. Venneri MA, Giannetta E, Panio G et al. Chronic inhibition of PDE5 limits pro-inflammatory monocyte-macrophage polarization in streptozotocin-induced diabetic mice. PLoS One 2015; 10.
18. Mokry J, Urbanova A, Medvedova I et al. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs. J Physiol Pharmacol. 2017; 68: 721–30.
19. Islam BN, Sharman SK, Hou Y et al. Sildenafil suppresses inflammation-driven colorectal cancer in mice. Cancer Prev Res 2017; 10: 377–88.
20. El-Naa MM, Othman M, Younes S. Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis. Drug Des Devel Ther 2016; 10: 3661.
21. Dorey G. Are erectile and ejaculatory dysfunction associated with postmicturition dribble? Urol Nurs 2003; 23: 42–5, 48–52.
22. De Nunzio C, Roehrborn CG, Andersson KE, McVary KT. Erectile dysfunction and lower urinary tract symptoms. Eur Urol Focus 2017; 3: 352–63.
23. Sexton CC, Coyne KS, Kopp ZS et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009; 103 (Suppl. 3): 12–23.
24. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306–14.
25. Maserejian NN, Kupelian V, McVary KT et al. Prevalence of postmicturition symptoms in association with lower urinary tract symptoms and health-related quality of life in men and women. BJU Int 2011; 108: 1452–8.
26. Poyhonen A, Auvinen A, Koskimaki J et al. Prevalence and bother of postmicturition dribble in finnish men aged 30–80 years: tampere ageing male urologic study (TAMUS). Scand J Urol Nephrol 2012; 46: 418–23.
27. Coyne KS, Sexton CC, Thompson CL et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int 2009; 104: 352–60.
28. Agarwal A, Eryuzlu LN, Cartwright R et al. What is the most bothersome lower urinary tract symptom? Individual- and populationlevel perspectives for both men and women. Eur Urol 2014; 65: 1211–7.
29. Poyhonen A, Auvinen A, Hakkinen JT et al. Population-level and individual-level bother of lower urinary tract symptoms among 30- to 80-year-old men. Urology 2016; 95: 164–70.
30. Yang DY, Ko K, Lee SH et al. Postmicturition dribble is associated with erectile dysfunction in middle-aged and older men with lower urinary tract symptoms. World J Mens Health 2018; 36: 263–70.
31. Macfarlane GJ, Botto H, Sagnier PP et al. The relationship between sexual life and urinary condition in the French community. J Clin Epidemiol 1996; 49: 1171–6.
32. Frankel SJ, Donovan JL, Peters TI et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998; 51: 677–85.
33. Shafik A, Shafik IA, El Sibai O, Shafik AA. Study of the response of the penile corporal tissue and cavernosus muscles to micturition. BMC Urol 2008; 8: 4.
34. Ferrer JE, Velez JD, Herrera AM. Age-related morphological changes in smooth muscle and collagen content in human corpus cavernosum. J Sex Med 2010; 7: 2723–8.
35. Costa C, Vendeira P. Does erectile tissue angioarchitecture modify with aging? An immunohistological and morphometric approach. J Sex Med 2008; 5: 833–40.
36. Giuliano F, Uckert S, Maggi M et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 2013; 63: 506–16.
37. Урология. Российские клинические рекомендации. Под ред. Ю.Г.Аляева, П.В.Глыбочко, Д.Ю.Пушкаря. М., 2017.
[Urology. Russian clinical guidelines. Ed.: Yu.G.Alaev, P.V.Glybochko, D.Y.Pushkar. Moscow, 2017 (in Russian).]
38. Говоров А.В., Касян Г.Р., Васильев А.О., Пушкарь Д.Ю. Тадалафил в лечении симптомов со стороны нижних мочевых путей: обзор литературы и существующей клинической практики в России. Consilium Medicum. 2014; 16 (7): 33–41.
[Govorov A.V., Kasyan G.R., Vasil’ev A.O., Pushkar D.Yu. Adalafil in the treatment of symptoms from the lower urinary tract: a review of literature and existing clinical practice in Russia. Consilium Medicum. 2014; 16 (7): 33–41 (in Russian).]
39. Камалов А.А., Охоботов Д.А., Тахирзаде А.М. и др. Комбинированная терапия больных с симптомами нижних мочевых путей и эректильной дисфункцией. Естественные и технические науки. 2013; 1: 105–13.
[Kamalov A.A., Okhobotov D.A., Takhirzade A.M. et al. Kombinirovannaia terapiia bol'nykh s simptomami nizhnikh mochevykh putei i erektil'noi disfunktsiei. Estestvennye i tekhnicheskie nauki. 2013; 1: 105–13 (in Russian).]
40. Gacci M, Andersson KE, Chapple C et al. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol 2016; 70 (1): 124–33.
41. Brock GB, McVary KT, Roehrborn CG et al. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. J Urol 2014; 191 (2): 405–11.
42. Gacci MI, Corona G, Salvi M et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61 (5): 994–1003.
43. Giuliano FI, Oelke M, Jungwirth A et al. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study. J Sex Med 2013; 10 (3): 857–65.
44. European association of urology. Guidelines. Management of Non-neurogenic Male LUTS. S. Gravas (Chair), J.N. Cornu, M. Gacci, C. Gratzke, T.R.W. Herrmann, C. Mamoulakis, M. Rieken, M.J. Speakman, K.A.O. Tikkinen, 2019.
45. Mujoo K, Sharin VG, Martin E et al. Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation. Nitric Oxide – Biol Chem 2010; 22: 43–50.
46. Sotolongo A, Mónica FZ, Kots A et al. Epigenetic regulation of soluble guanylate cyclase (sGC) b1 in breast cancer cells. FASEB J 2016; 30: 3171–80.
47. Lin JE, Li P, Snook AE et al. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology 2010; 138: 241–54.
48. Rappaport JA, Waldman SA. The guanylate cyclase C – cGMP signaling axis opposes intestinal epithelial injury and neoplasia. Front Oncol 2018; 8: 299.
49. Liu N, Mei L, Fan X et al. Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway. Cancer Lett 2016; 378: 38–50.
50. Egerdie RB, Auerbach S, Roehrborn CG et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, doubleblind study. J Sex Med 2012; 9: 271–81.
51. Волков А.А., М.И. Петричко, Н.В. Будник. Ежедневный прием ингибиторов фосфодиэстеразы 5-го типа – коррекция эректильной дисфункции и симптомов нижних мочевых путей у больных аденомой предстательной железы. Урология. 2014; 4: 64–8.
[Volkov A.A., Petrichko M.I., Budnik N.V. Daily use of type 5 phosphodiesterase inhibitors – correction of erectile dysfunction and lower urinary tract symptoms in patients with prostate adenoma. Urologija. 2014; 4: 64–8 (In Russian).]
52. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401–7.
53. Bechara A, Romano S, Casabé A et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008; 5: 2170–8.
54. Porst H, McVary KT, Montorsi F et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56: 727–36.
55. Roehrborn CG, McVary KT, Elion-Mboussa A et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228–34.
________________________________________________
2. Gacci M et al. PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH. Curr Bladder Dysfunction Rep 2013; 8: 150–9.
3. Gacci M et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011; 60: 809–25.
4. Mondul AM, Rimm EB, Giovannucci E et al. A Prospective Study of Lower Urinary Tract Symptoms and Erectile Dysfunction. J Urol 2008; 179 (6): 2321–6.
5. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281 (6): 537–44.
6. Blanker MH, Bohnen AM, Groeneveld FP et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001; 49 (4): 436–42.
7. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44 (6): 637–49.
8. Kamalov A.A., Takhirzade A.M. Sovremennye podkhody k konservativnomu lecheniiu muzhchin s sochetaniem dobrokachestvennoi giperplazii predstatel'noi zhelezy i erektil'noi disfunktsii. Urologiia. 2017; 6: 160–3 (in Russian).
9. Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol 2011; 483–94.
10. Daneshgari F, Liu G, Hanna-Mitchell AT. Path of translational discovery of urological complications of obesity and diabetes. Am J Physiol – Ren Physiol 2017; 312: F887–F896.
11. Lu T, Lin W-J, Izumi K et al. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Mol Endocrinol 2012; 26: 1707–15.
12. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 2012; 367: 248–57.
13. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401–7.
14. Toque HA, Teixeira CE, Priviero FBM et al. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol 2008; 154: 787–96.
15. Toque HA, Teixeira CE, Lorenzetti R et al. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol 2008; 591: 189–95.
16. Toque HA, Priviero FBM, Teixeira CE et al. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release. Urology 2009; 74: 216–21.
17. Venneri MA, Giannetta E, Panio G et al. Chronic inhibition of PDE5 limits pro-inflammatory monocyte-macrophage polarization in streptozotocin-induced diabetic mice. PLoS One 2015; 10.
18. Mokry J, Urbanova A, Medvedova I et al. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs. J Physiol Pharmacol. 2017; 68: 721–30.
19. Islam BN, Sharman SK, Hou Y et al. Sildenafil suppresses inflammation-driven colorectal cancer in mice. Cancer Prev Res 2017; 10: 377–88.
20. El-Naa MM, Othman M, Younes S. Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis. Drug Des Devel Ther 2016; 10: 3661.
21. Dorey G. Are erectile and ejaculatory dysfunction associated with postmicturition dribble? Urol Nurs 2003; 23: 42–5, 48–52.
22. De Nunzio C, Roehrborn CG, Andersson KE, McVary KT. Erectile dysfunction and lower urinary tract symptoms. Eur Urol Focus 2017; 3: 352–63.
23. Sexton CC, Coyne KS, Kopp ZS et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009; 103 (Suppl. 3): 12–23.
24. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306–14.
25. Maserejian NN, Kupelian V, McVary KT et al. Prevalence of postmicturition symptoms in association with lower urinary tract symptoms and health-related quality of life in men and women. BJU Int 2011; 108: 1452–8.
26. Poyhonen A, Auvinen A, Koskimaki J et al. Prevalence and bother of postmicturition dribble in finnish men aged 30–80 years: tampere ageing male urologic study (TAMUS). Scand J Urol Nephrol 2012; 46: 418–23.
27. Coyne KS, Sexton CC, Thompson CL et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int 2009; 104: 352–60.
28. Agarwal A, Eryuzlu LN, Cartwright R et al. What is the most bothersome lower urinary tract symptom? Individual- and populationlevel perspectives for both men and women. Eur Urol 2014; 65: 1211–7.
29. Poyhonen A, Auvinen A, Hakkinen JT et al. Population-level and individual-level bother of lower urinary tract symptoms among 30- to 80-year-old men. Urology 2016; 95: 164–70.
30. Yang DY, Ko K, Lee SH et al. Postmicturition dribble is associated with erectile dysfunction in middle-aged and older men with lower urinary tract symptoms. World J Mens Health 2018; 36: 263–70.
31. Macfarlane GJ, Botto H, Sagnier PP et al. The relationship between sexual life and urinary condition in the French community. J Clin Epidemiol 1996; 49: 1171–6.
32. Frankel SJ, Donovan JL, Peters TI et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998; 51: 677–85.
33. Shafik A, Shafik IA, El Sibai O, Shafik AA. Study of the response of the penile corporal tissue and cavernosus muscles to micturition. BMC Urol 2008; 8: 4.
34. Ferrer JE, Velez JD, Herrera AM. Age-related morphological changes in smooth muscle and collagen content in human corpus cavernosum. J Sex Med 2010; 7: 2723–8.
35. Costa C, Vendeira P. Does erectile tissue angioarchitecture modify with aging? An immunohistological and morphometric approach. J Sex Med 2008; 5: 833–40.
36. Giuliano F, Uckert S, Maggi M et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 2013; 63: 506–16.
37. Urology. Russian clinical guidelines. Ed.: Yu.G.Alaev, P.V.Glybochko, D.Y.Pushkar. Moscow, 2017 (in Russian).
38. Govorov A.V., Kasyan G.R., Vasil’ev A.O., Pushkar D.Yu. Adalafil in the treatment of symptoms from the lower urinary tract: a review of literature and existing clinical practice in Russia. Consilium Medicum. 2014; 16 (7): 33–41 (in Russian).
39. Kamalov A.A., Okhobotov D.A., Takhirzade A.M. et al. Kombinirovannaia terapiia bol'nykh s simptomami nizhnikh mochevykh putei i erektil'noi disfunktsiei. Estestvennye i tekhnicheskie nauki. 2013; 1: 105–13 (in Russian).
40. Gacci M, Andersson KE, Chapple C et al. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol 2016; 70 (1): 124–33.
41. Brock GB, McVary KT, Roehrborn CG et al. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. J Urol 2014; 191 (2): 405–11.
42. Gacci MI, Corona G, Salvi M et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61 (5): 994–1003.
43. Giuliano FI, Oelke M, Jungwirth A et al. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study. J Sex Med 2013; 10 (3): 857–65.
44. European association of urology. Guidelines. Management of Non-neurogenic Male LUTS. S. Gravas (Chair), J.N. Cornu, M. Gacci, C. Gratzke, T.R.W. Herrmann, C. Mamoulakis, M. Rieken, M.J. Speakman, K.A.O. Tikkinen, 2019.
45. Mujoo K, Sharin VG, Martin E et al. Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation. Nitric Oxide – Biol Chem 2010; 22: 43–50.
46. Sotolongo A, Mónica FZ, Kots A et al. Epigenetic regulation of soluble guanylate cyclase (sGC) b1 in breast cancer cells. FASEB J 2016; 30: 3171–80.
47. Lin JE, Li P, Snook AE et al. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology 2010; 138: 241–54.
48. Rappaport JA, Waldman SA. The guanylate cyclase C – cGMP signaling axis opposes intestinal epithelial injury and neoplasia. Front Oncol 2018; 8: 299.
49. Liu N, Mei L, Fan X et al. Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway. Cancer Lett 2016; 378: 38–50.
50. Egerdie RB, Auerbach S, Roehrborn CG et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, doubleblind study. J Sex Med 2012; 9: 271–81.
51. Volkov A.A., Petrichko M.I., Budnik N.V. Daily use of type 5 phosphodiesterase inhibitors – correction of erectile dysfunction and lower urinary tract symptoms in patients with prostate adenoma. Urologija. 2014; 4: 64–8 (In Russian).
52. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401–7.
53. Bechara A, Romano S, Casabé A et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008; 5: 2170–8.
54. Porst H, McVary KT, Montorsi F et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56: 727–36.
55. Roehrborn CG, McVary KT, Elion-Mboussa A et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228–34.
Авторы
А.Ю. Цуканов*, С.П. Семикина
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*tsoukanov2000@mail.ru
Omsk State Medical University, Omsk, Russia
*tsoukanov2000@mail.ru
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*tsoukanov2000@mail.ru
________________________________________________
Omsk State Medical University, Omsk, Russia
*tsoukanov2000@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.